Part 1: Repository Architecture

1.1 Unifying Research Question

The portfolio is organized around a tractably scoped dissertation question anchored in a single procedure category and one intervention class: Does preoperative initiation of multimodal non-opioid analgesia suppress perioperative central sensitization biomarkers and reduce CPSP incidence at 12 months in high-risk total knee arthroplasty patients? This framing is procedure-specific (TKA, where incidence data and existing scoping review work are most mature), mechanistically grounded (central sensitization suppression as the measurable intermediate), and anchored to a clinically definable primary endpoint.

The portfolio's broader organizing question — what are the mechanistic, pharmacological, and clinical determinants of acute-to-chronic pain transition in the surgical patient, and how can perioperative analgesic strategy be optimized to reduce that transition at the population level? — functions as the long-term research program from which the dissertation question is drawn. Agent selection, dose optimization, risk phenotyping, and cross-procedure generalization are repositioned as specific aims and future directions rather than components of the primary question. Every working paper in the corpus is a facet of this program — mechanistic, epidemiological, pharmacological, translational, or clinical implementation — exactly as WP-2026 treats legal-economic coercion as a single unifying problem addressed from multiple analytical angles.

1.2 Repository Taxonomy

The repository contains six document types, parallel to WP-2026. Each type has a designated prefix, governing methodology standard, and scaffolding role.

1.3 Corpus Architecture: 24 Working Papers

The twenty-four papers below scaffold from broad evidence mapping through mechanistic analysis, pharmacological assessment, and research design, terminating in the dissertation prospectus and doctoral pathway documents. Papers marked COMPLETE are existing documents. Papers marked PRIORITY are the recommended next productions.

Cluster A — Evidence Mapping: Scoping Reviews and Meta-Analysis (SR-01 through SR-05, MA-01)

Cluster B — Mechanistic Analysis: Central Sensitization and Neuroinflammation (ME-01 through ME-05)

The ME cluster documents the molecular and cellular biology of CPSP. For neuroscience PhD applications, ME-01 and ME-02 are the primary evidence of mechanistic competency and must engage the primary literature at the depth expected by pain neuroscience faculty. See Section 1.5 for neuroscience PhD pathway guidance.

Cluster C — Pharmacological Assessment (PH-01 through PH-05)

Cluster D — Research Design and Translational Bridge (RD-01 through RD-04)

Cluster E — Capstone and Application Documents (PR-01 through PR-04)

1.4 Scaffolding Logic and Production Sequence

The production sequence below is the recommended order of completion. Each paper feeds forward into subsequent documents. Phase 2b (MA-01) runs in parallel with Phase 2 and is not a blocker for Phase 3.

1.5 Neuroscience PhD Pathway Branch

This section provides application-facing guidance for targeting standalone neuroscience PhD programs as a parallel pathway to MD-PhD MSTP. The underlying portfolio is the same; the application narrative, faculty targeting strategy, and document emphasis differ.

Rationale for Portfolio Alignment

The CPSP/perioperative pain focus is substantively positioned for neuroscience PhD programs. Central sensitization, dorsal horn plasticity, NMDA receptor dynamics, neuroinflammatory cascades, microglial activation, and descending inhibitory pathway dysfunction are core neuroscience research problems — not exclusively clinical pharmacology. The ME cluster documents this mechanistic layer directly. Target programs with strong pain neuroscience tracks include UCSF (Wheeler Center for Neurobiology of Addiction, Pain, and Health), UW (Department of Physiology and Biophysics, Neuroscience Graduate Program), University of Pittsburgh (Center for Neuroscience), and University of Michigan (Neuroscience Graduate Program).

Portfolio Re-Emphasis for Neuroscience PhD Applications

Faculty Targeting Framework

Neuroscience PhD applications require named faculty targets with specific laboratory alignment statements. PR-04 must include at least two named faculty targets per program with explicit mapping between the candidate's ME and RD cluster work and the faculty member's active research program. The CPSP mechanistic framework provides natural alignment with laboratories working on: (1) spinal cord plasticity and long-term potentiation of pain synapses; (2) microglial and astrocytic contributions to central sensitization; (3) neuroinflammatory mechanisms of chronic pain; and (4) translational biomarker development for pain phenotyping.

Representative faculty alignment targets by program are provided below as a governed starting point for PR-04. These must be verified against current lab activity and updated to reflect actual research fit at the time of application.

Separation of Application Narratives

PR-03 (MD-PhD application) and PR-04 (neuroscience PhD application) are distinct documents with different register, emphasis, and audience. PR-03 foregrounds the clinical translation arc: clinical laboratory background, anesthesiology shadowing, perioperative medicine as the application domain, and the CPSP prevention trial as the dissertation vehicle. PR-04 foregrounds the basic science arc: mechanistic curiosity about dorsal horn plasticity and neuroinflammation, the ME cluster as primary intellectual contribution, and the translational biomarker study as the bridge to clinical relevance. The same portfolio underlies both; the framing must be genuinely distinct — not a reworded version of PR-03.

Part 2: Dissertation Prospectus

PR-01 — Version 2.0 — March 2026

KEY INTERPRETATIONS

2.1 Research Question and Significance

Chronic post-surgical pain (CPSP) — defined as pain persisting beyond three months after surgery in the absence of pre-existing chronic pain — represents a major unresolved clinical problem in perioperative medicine. Kehlet et al. (Lancet, 2006; PMID 16698416) established that CPSP affects 10–50% of surgical patients depending on procedure, with incidence as high as 50–85% following thoracotomy and 5–30% following total knee arthroplasty. These figures translate to millions of patients annually in the United States who develop persistent pain as a direct consequence of surgical intervention.

The perioperative window is mechanistically the highest-yield intervention point for CPSP prevention. Central sensitization — the sustained increase in excitability of nociceptive neurons in the dorsal horn driven by NMDA receptor activation, microglial recruitment, and descending inhibitory pathway dysfunction — is established during the perioperative period by repeated nociceptive input from surgical tissue injury [Woolf, Pain 2011; PMID 22078064]. Once established, central sensitization persists independently of peripheral input and drives chronic pain states. Pharmacological suppression of this process during the operative and immediate postoperative period represents the primary mechanistic rationale for perioperative analgesic optimization.

The central dissertation question is tractably scoped to one procedure category and one intervention class: Does preoperative initiation of multimodal non-opioid analgesia suppress perioperative central sensitization biomarkers and reduce CPSP incidence at 12 months in high-risk total knee arthroplasty patients? This framing is procedure-specific (TKA, where incidence data and existing scoping review work are most mature), mechanistically grounded (central sensitization suppression as the measurable intermediate), and anchored to a clinically definable primary endpoint. Agent selection, dose optimization, risk phenotyping, and cross-procedure generalization are repositioned as specific aims and future directions feeding a larger research program rather than components of the primary question.

2.2 Theoretical and Mechanistic Framework

The dissertation operates within a two-axis mechanistic framework: (1) the peripheral-to-central sensitization cascade as the biological mechanism of CPSP development, and (2) the multimodal pharmacological interruption of that cascade as the intervention logic.

Peripheral sensitization — driven by prostaglandin E2, bradykinin, substance P, and inflammatory cytokine release at the surgical site — produces primary hyperalgesia and initiates afferent nociceptive barrage. This barrage recruits NMDA receptors at dorsal horn synapses, triggering calcium influx, protein kinase C activation, and removal of the Mg²⁺ voltage block that maintains the resting nociceptive threshold. Sustained NMDA activation produces wind-up — progressive amplification of dorsal horn neuron response — which, if uninterrupted, produces long-term potentiation of pain synapses and structural reorganization of spinal pain circuits [Ji et al., Nature Reviews Neuroscience 2018; PMID 29371059].

The pharmacological intervention framework targets four nodes in this cascade: (1) NMDA receptor blockade via subanesthetic ketamine to suppress wind-up; (2) α2-agonist mediated inhibition of norepinephrine release and sympathoadrenal activation via dexmedetomidine; (3) voltage-gated calcium channel α2δ subunit inhibition via pregabalin or gabapentin to reduce excitatory neurotransmitter release; and (4) sodium channel blockade via intravenous lidocaine to suppress ectopic discharge in injured peripheral nociceptors. Regional anesthetic techniques function as a fifth node, interrupting afferent input at the site of surgical injury before central sensitization is initiated.

2.3 Specific Aims

2.4 Methods Overview

Aims 1 and 2 employ systematic review methodology (PRISMA-ScR/JBI and PRISMA/Cochrane respectively). Aim 1 uses a scoping framework without meta-analytic pooling given expected heterogeneity in CPSP measurement instruments, follow-up duration, and procedure categories. Aim 2 restricts pooling to studies applying the IASP CPSP definition with minimum 3-month follow-up as an explicit inclusion criterion. This restriction is necessary because the same definitional heterogeneity that precludes pooling in Aim 1 does not resolve absent this constraint. A narrative synthesis is the pre-specified primary output; random-effects pooling is contingent on I² assessment at the screening stage confirming sufficient homogeneity.

Aim 3 specifies a multi-arm adaptive platform trial using response-adaptive randomization informed by Bayesian interim analyses, conducted in accordance with FDA 2019 adaptive design guidance. Statistical operating characteristics, DSMB requirements, and IRB pre-specification procedures are addressed as distinct subsections in RD-02. The primary endpoint is CPSP presence at 12 months post-TKA, defined as pain ≥3/10 on the Numerical Rating Scale with functional interference on the Pain Disability Index, in the absence of surgical complication or recurrent pathology. Secondary endpoints include opioid consumption at 24 and 48 hours, acute pain NRS at 4, 12, and 24 hours, length of stay, PONV incidence, and patient-reported outcomes at 3 and 6 months.

Aim 4 specifies a nested translational sub-study with blood sampling at five timepoints: preoperative baseline, post-induction, intraoperative at 60 minutes, PACU arrival, and POD 1. The primary confirmatory panel — IL-6, BDNF, and CGRP — is restricted to three markers to preserve statistical power, with a priori power calculations specified for each marker individually. Multiplex cytokine assay (Luminex platform) for confirmatory markers; individual ELISAs for exploratory markers. Exploratory markers (IL-1β, TNF-α, IL-10, substance P) analyzed with Benjamini-Hochberg FDR correction, not Bonferroni, given their exploratory rather than confirmatory status.

2.5 Significance and Innovation

CPSP prevention represents an unmet clinical need of substantial magnitude. Gaskin and Richard (Journal of Pain, 2012; PMID 22607834) estimated the total economic burden of chronic pain in the United States at $560–635 billion annually in direct health care costs and lost productivity, calculated in 2010 dollars — a figure encompassing both surgical and non-surgical chronic pain that establishes the order-of-magnitude scope of the problem. At the procedure level, TKA-associated CPSP has been associated with persistent analgesic requirements, functional limitation, and reduced patient-reported outcome scores at 12 months in 5–30% of patients across published cohorts [Kehlet et al., Lancet 2006; PMID 16698416], with corresponding downstream costs in revision consultation, pain clinic utilization, and long-term opioid prescribing. Over one million TKA procedures are performed annually in the United States; a perioperative intervention demonstrably reducing CPSP incidence by 20–30% in high-risk patients within this procedure category represents a tractable, measurable reduction in that burden.

The innovation of this dissertation is threefold. First, it treats CPSP incidence — not acute pain scores — as the primary clinical target in a single high-volume procedure category, reframing perioperative analgesia as a prevention intervention with a measurable long-term endpoint rather than a comfort measure assessed at 24 hours. Second, it integrates preoperative risk phenotyping into the trial design, enabling stratified analysis of intervention effects by sensitization status — a methodological advance over existing RCTs that enroll unselected TKA populations. Third, it links perioperative pharmacological intervention to a prospectively measured neuroinflammatory biomarker panel with a priori power calculations per marker, providing mechanistic evidence for observed clinical effects and a translational bridge to future multi-procedure generalization.

For an MD-PhD or neuroscience PhD candidate, this portfolio demonstrates independent research productivity — three submission-ready scoping reviews, a mechanistic framework corpus, and a fully specified adaptive trial design — prior to matriculation. The portfolio functions as both a pre-built research identity and a live analytical product, arriving at doctoral training with a functioning publication record and a dissertation question already operationalized across two doctoral application pathways.

END OF DOCUMENT — CM-BIO-ARCH-01 · PERIOPERATIVE PAIN SYSTEMS RESEARCH PORTFOLIO · REPOSITORY ARCHITECTURE, DISSERTATION PROSPECTUS, AND DOCTORAL PATHWAY FRAMEWORK · V2.0 · MARCH 2026 · UNCONTROLLED COPY